{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:43:40Z","timestamp":1759693420460,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mehy.2021.110506","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T20:34:14Z","timestamp":1611261254000},"page":"110506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Relationship between clozapine dose and severity of obsessive-compulsive symptoms"],"prefix":"10.1016","volume":"148","author":[{"given":"David D.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Evelyn","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall F.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mehy.2021.110506_b0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2021.110506_b0010","doi-asserted-by":"crossref","first-page":"e0199758","DOI":"10.1371\/journal.pone.0199758","article-title":"Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.mehy.2021.110506_b0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-015-1807-1","article-title":"Treatment of clozapine-associated weight gain: a systematic review","volume":"71","author":"Whitney","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.mehy.2021.110506_b0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fnins.2018.00203","article-title":"Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review","volume":"12","author":"Yuen","year":"2018","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1503\/jpn.170135","article-title":"Clozapine, elevated heart rate and QTc prolongation","volume":"43","author":"Kim","year":"2018","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1503\/jpn.180087","article-title":"Clozapine-induced obsessive\u2013compulsive symptoms: mechanisms and treatment","volume":"44","author":"Kim","year":"2019","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000505876","article-title":"Clozapine-associated obsessive-compulsive symptoms and their management: a systematic review and analysis of 107 reported cases","volume":"89","author":"Kim","year":"2020","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2021.110506_b0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The yale-brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"16","key":"10.1016\/j.mehy.2021.110506_b0055","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1017\/S003329171800017X","article-title":"Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia","volume":"48","author":"Fernandez-Egea","year":"2018","journal-title":"Psychol Med"},{"issue":"11","key":"10.1016\/j.mehy.2021.110506_b0060","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4088\/JCP.11m07164","article-title":"Genetic Risk and Outcome of Psychosis Investigators. obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients","volume":"73","author":"Beduin","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2021.110506_b0065","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1017\/S0033291711000419","article-title":"Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia","volume":"41","author":"Schirmbeck","year":"2011","journal-title":"Psychol Med"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms","volume":"28","author":"Lin","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1440-1819.2005.01362.x","article-title":"Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients","volume":"59","author":"Ertugrul","year":"2005","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.comppsych.2013.09.001","article-title":"Obsessive compulsive symptoms in patients with Schizophrenia on Clozapine and with Obsessive Compulsive disorder: a comparison study","volume":"55","author":"Doyle","year":"2014","journal-title":"Compr Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2021.110506_b0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00002826-199619040-00003","article-title":"Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients","volume":"19","author":"Poyurovsky","year":"1996","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2021.110506_b0095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.mehy.2021.110506_b0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.mehy.2021.110506_b0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.comppsych.2015.08.007","article-title":"Defining clinical severity in adults with obsessive-compulsive disorder","volume":"63","author":"Storch","year":"2015","journal-title":"Compr Psychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1037\/a0035174","article-title":"Defining clinical severity in pediatric obsessive-compulsive disorder","volume":"26","author":"Lewin","year":"2014","journal-title":"Psychol Assess"},{"year":"2019","series-title":"R: A language and environment for statistical computing","author":"R Core Team","key":"10.1016\/j.mehy.2021.110506_b0115"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000012321","article-title":"Development of obsessive-compulsive symptoms during clozapine treatment in schizophrenia and its positive response to clomipramine","volume":"68","author":"Biondi","year":"1999","journal-title":"Psychother Psychosom"},{"issue":"6","key":"10.1016\/j.mehy.2021.110506_b0125","doi-asserted-by":"crossref","first-page":"973a","DOI":"10.1176\/ajp.156.6.973a","article-title":"Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features","volume":"156","author":"Strous","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004850-200015030-00006","article-title":"Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms","volume":"15","author":"Poyurovsky","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2021.110506_b0135","first-page":"286","article-title":"Clozapine-induced obsessions and compulsions successfully treated with behaviour therapy: a case report and literature review","volume":"49","author":"MacCabe","year":"2001","journal-title":"Schizophr Res"},{"issue":"12","key":"10.1016\/j.mehy.2021.110506_b0140","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4088\/JCP.v63n1214b","article-title":"Behavior therapy attenuates clozapine-induced obsessions and compulsions","volume":"63","author":"MacCabe","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.mehy.2021.110506_b0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1607-551X(09)70121-4","article-title":"Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature","volume":"20","author":"Ke","year":"2004","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2004-815525","article-title":"Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study","volume":"37","author":"Reznik","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.mehy.2021.110506_b0155","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2006.03.024","article-title":"Benefits of combining aripiprazole to clozapine: three case reports","volume":"30","author":"Rocha","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"04","key":"10.1016\/j.mehy.2021.110506_b0160","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4088\/JCP.v68n0408","article-title":"De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study","volume":"68","author":"Mahendran","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0165","first-page":"86","article-title":"Treatment approach in case of comorbidity of obsessive-compulsive disorder in schizophrenia: efficacy and side effects of clozapine and chlorimipramine","volume":"25","author":"Papazisis","year":"2007","journal-title":"Epitheorese Klinikes Farmakologias kai Farmakokinetikes"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00048670601172806","article-title":"Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia","volume":"41","author":"Zink","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"10.1016\/j.mehy.2021.110506_b0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-2007-985885","article-title":"Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms","volume":"40","author":"Zink","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0180","first-page":"155","article-title":"Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia","volume":"19","author":"Coskun","year":"2009","journal-title":"Klinik Psikofarmakoloji B\u00fclteni\/Bulletin of Clinical Psychopharmacology"},{"issue":"4","key":"10.1016\/j.mehy.2021.110506_b0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNF.0b013e31819cc8e6","article-title":"Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole","volume":"32","author":"Englisch","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0190","first-page":"58","article-title":"Obsessive-compulsive symptoms following clozapine administration","volume":"17","author":"Aggarwal","year":"2010","journal-title":"Primary Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0195","first-page":"65","article-title":"Suicidal obsessions as dose dependent side-effect of clozapine","volume":"44","author":"Aukst-Margeti\u0107","year":"2011","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 1","key":"10.1016\/j.mehy.2021.110506_b0200","first-page":"293","article-title":"Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with risperidone and clozapine in an adolescent girl \u2013 a case report","volume":"35","author":"Marsani\u0107","year":"2011","journal-title":"Coll Antropol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0205","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/YCT.0b013e3181ec0d64","article-title":"Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: a case report","volume":"27","author":"Rao","year":"2011","journal-title":"J ECT"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1744-859X-12-40","article-title":"Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia","volume":"12","author":"Ery\u0131lmaz","year":"2013","journal-title":"Ann Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2021.110506_b0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/WNF.0000000000000079","article-title":"Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report","volume":"38","author":"Chiou","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2021.110506_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5064047","article-title":"Treatment of hypochondriasis in two schizophrenia patients using clozapine","volume":"2017","author":"Tundo","year":"2017","journal-title":"Case Rep Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/JCP.0000000000000817","article-title":"Abrupt improvement in obsessive-compulsive symptoms upon discontinuation of clozapine","volume":"38","author":"Dykema","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.mehy.2021.110506_b0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajp.2018.10.013","article-title":"Effectiveness of tDCS augmentation for co-morbid obsessive compulsive disorder in chronic schizophrenia: a case report","volume":"38","author":"Verma","year":"2018","journal-title":"Asian J Psychiatr"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0235","first-page":"449","article-title":"Management of obsessive compulsive disorder induced by the use of clozapine","volume":"8","author":"Donmez","year":"2019","journal-title":"Med Sci (Turkey)"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pnp.523","article-title":"Clozapine in treatment-resistant schizophrenia: a patient's journey","volume":"23","author":"Korsavva","year":"2019","journal-title":"Prog Neurol Psychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0245","doi-asserted-by":"crossref","first-page":"472","DOI":"10.21037\/apm.2020.02.22","article-title":"Antipsychotics-associated obsessive-compulsive symptoms: individualized treatments and clinical benefits of memantine: a case report","volume":"9","author":"Li","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"4","key":"10.1016\/j.mehy.2021.110506_b0250","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JCP.0000000000001214","article-title":"Adjunct aripiprazole for obsessive-compulsive symptoms associated with second-generation antipsychotics in 2 patients with schizophrenia: anti-obsessional efficacy of partial agonism","volume":"40","author":"Yesilkaya","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1124\/jpet.111.183780","article-title":"Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo","volume":"339","author":"Yadav","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.mehy.2021.110506_b0260","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0028-3908(95)00170-0","article-title":"Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors","volume":"35","author":"Newman-Tancredi","year":"1996","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.mehy.2021.110506_b0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/107385840000600408","article-title":"The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?","volume":"6","author":"Roth","year":"2000","journal-title":"The Neuroscientist"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","article-title":"Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review","volume":"10","author":"Schirmbeck","year":"2012","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110506_b0280","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1192\/bjp.165.2.267","article-title":"Obsessive-compulsive symptoms and clozapine","volume":"165","author":"Dursun","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.mehy.2021.110506_b0285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbr.2013.01.005","article-title":"5-HT2C receptor involvement in the control of persistence in the reinforced spatial alternation animal model of obsessive-compulsive disorder","volume":"243","author":"Papakosta","year":"2013","journal-title":"Behav Brain Res"},{"issue":"6","key":"10.1016\/j.mehy.2021.110506_b0290","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1017\/S146114570800847X","article-title":"The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder","volume":"11","author":"Flaisher-Grinberg","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.mehy.2021.110506_b0295","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.pnpbp.2004.06.002","article-title":"Clozapine-induced obsessive-compulsive symptoms","volume":"28","author":"MacCabe","year":"2004","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.mehy.2021.110506_b0300","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000491700","article-title":"Reversal of dopamine supersensitivity as a mechanism of action of clozapine","volume":"87","author":"Kim","year":"2018","journal-title":"Psychother Psychosom"},{"issue":"1","key":"10.1016\/j.mehy.2021.110506_b0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","article-title":"Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study","volume":"18","author":"Wetzel","year":"1998","journal-title":"J Clin Psychopharmacol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:32Z","timestamp":1759692212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":61,"alternative-id":["S0306987721000244"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110506","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between clozapine dose and severity of obsessive-compulsive symptoms","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110506"}}